1. Home
  2. DXLG vs ACET Comparison

DXLG vs ACET Comparison

Compare DXLG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Destination XL Group Inc.

DXLG

Destination XL Group Inc.

HOLD

Current Price

$0.50

Market Cap

38.2M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.01

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXLG
ACET
Founded
1976
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.2M
69.6M
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
DXLG
ACET
Price
$0.50
$7.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$2.50
$65.33
AVG Volume (30 Days)
125.7K
174.7K
Earning Date
04-14-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.82
EPS
N/A
N/A
Revenue
$467,015,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.45
52 Week High
$2.09
$9.05

Technical Indicators

Market Signals
Indicator
DXLG
ACET
Relative Strength Index (RSI) 32.38 48.89
Support Level N/A $0.62
Resistance Level $0.73 $8.46
Average True Range (ATR) 0.06 0.53
MACD 0.00 -0.08
Stochastic Oscillator 11.88 50.43

Price Performance

Historical Comparison
DXLG
ACET

About DXLG Destination XL Group Inc.

Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: